Shareef Antar

Over see the construction and management of the In-Vitro ADME laboratory for Villapharma Research which is a part of Eurofins Discovery (https://www.eurofinsdiscoveryservices.com/)

Supporting and giving demos to customers in the DACH region for the Infinite, Spark, and Spark Cyto plate readers, and Resolvex.

Developing and performing Bioanalytical Methods for promoting by using Tecan-SP (SPE columns and Positive Pressure Manifold , M10 and A200) and Tecan products (EVO and Fluent).

Developing and performing Bioanalytical Methods for both GLP and non-GLP studies as a Study Director. These studies consist of the following: ADME In-Vitro Studies, and Toxicokinetics and Pharmacokinetics In-Vivo Studies.

Biological Mass Spectrometry and Biomarker Research Group: Apply both top-down and bottom-up workflows using UPLC and high resolution mass spectrometry (Waters nanoAcquity, LCT Premier XE, Xevo G2 Tof, Thermo LTQ Orbitrap XL, Velos, QExactive) to characterize protein therapeutics.

Grant funded position. Responsible as a Study Director for the bioanalytical animal studies for novel compounds, using LC/MS/MS for analytical detection and for pharmacokinetic analysis. Responsible as a Study Director for performing in-vitro ADME assays (i.e. hepatocyte, microsomal metabolic stability, and CYP DDI) and determining metabolites of novel compounds using LC/MS/MS

Research Specialist in the Proteomics Core Laboratory which is part of the Research Department of Weill Cornell Medical College in Qatar. Responsible for setting up and managing the Proteomics Core Laboratory.

Research Scientist in the Proteomics Core Laboratory which is part of the Biosciences and Bioengineering Department. Responsible for setting up and managing the Proteomics Core Laboratory.

Responsible as a Study Director for the bioanalytical animal studies for novel compounds, using LC/MS/MS for analytical detection and using WinNonlin for pharmacokinetic analysis and for performing in-vitro ADME assays (i.e. hepatocyte, microsomal metabolic stability, and CYP DDI) and determining metabolites of novel compounds using LC/MS/MS and fluorescence for analytical detection. Responsible for the semi-automation for these ADME assays and PK sample preparation using a Tecan Genesis 200 robot.

1- Responsible for the bioanalytical animal studies of Celgene’s novel compounds, using LC/MS/MS for analytical detection and using WinNonlin for pharmacokinetic analysis. 2- Performing in-vitro hepatocyte metabolic stability assay and determining metabolites of Celgene’s novel compounds using LC/MS/MS (Micromass LC, Thermo LTQ, and Sciex 4000). This data is reported in the preclinical reports which are read by the Discovery Groups.

Performing automated, high throughput in-vitro liver metabolic stability assays and determining metabolites of Roche’s novel compounds using LC/MS/MS (Micromass LC and Sciex 4000 Qtrap). This data is reported in the preclinical reports through ActivityBase software which are read by the Discovery Groups.

Performed automated, high throughput in-vitro liver and S9 metabolic stability assays and determined metabolites of Sanofi-Aventis’ novel compounds using LC/MS (Micromass single quad, Sciex 4000 Qtrap and Ion Trap). Data was reported in the preclinical reports through ActivityBase software which were read by the Discovery Groups.

1- Responsible for the bioanalytical animal studies of novel compounds, using LC/MS/MS for analytical detection and pharmacokinetic analysis in the Bioanalytical Group (BAPK). 2- Perform enzymatic (P450 and UGT isozymes) assays on novel (14C and 3H) radiolabeled compounds to determine its kinetics parameters (i.e., Km or Ki, Vmax, and IC50) of the parent compounds and also its corresponding metabolites using LC/MS/MS and LC/MS (Ion trap) in the ADME group.